Carbon dots derived from metformin by electrochemical synthesis with broad-spectrum antibacterial properties

Due to the advantages of good aqueous dispersion and biocompatibility, carbon dots (CDs) are promising candidates for a wide range of applications in the biological field. Notably, CDs derived from biosafe organic precursors will contribute both new types of CDs and new bioactivities. Herein, metformin (MET), a first-line drug for the treatment of type II diabetes, was selected as an organic precursor to fabricate a new type of CDs, namely, semi-carbonized MET (MCDs). These MCDs derived from MET possess a completely new antibacterial activity against Staphylococcus aureus (SA) and Escherichia coli (E. coli) compared with that of MET and achieve complete antibacterial activity at 200 mu g mL-1. The broad-spectrum antibacterial mechanism of MCDs involves two aspects. For the Gram-positive bacteria SA, MCDs mainly affect the transport of nutrients by adsorbing onto the surface of bacteria, thereby inhibiting bacterial growth. For the Gram-negative bacteria E. coli, MCDs can easily pass through their thin cell walls and stimulate the bacteria to produce excess ROS, eventually leading to the death of the bacteria. This work may open a new way for the future design and development of CDs prepared from biosafe organic precursors with specific functions. Carbon dots (MCDs) with broad-spectrum antibacterial properties were synthesized from metformin by electrochemical oxidation. MCDs mainly affect the transport of nutrients and stimulate oxidative stress in SA and E. coli, respectively.